Drug Trial Radar · NCT07902817
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
480
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jun 2029
Study completion Sep 2030
Sponsor
- Lead sponsor
- Jade Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.
Conditions
- IgA Nephropathy (IgAN)
Interventions
JADE101Drug
JADE101 is supplied as sterile solution to be administered by SC injection.
PlaceboDrug
Placebo is supplied as sterile solution to be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of JADE101 on Urine Protein Creatinine Ratio (UPCR) in participants with IgA nephropathyTime frame: Week 52
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Jade Clinical Site
Arvada, Colorado · Recruiting
Jade Clinical Site
Lauderdale Lakes, Florida · Recruiting
Jade Clinical Site
Atlanta, Georgia · Recruiting
Jade Clinical Site
Katy, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.